GATA3 and breast carcinoma: To further explore the role of GATA3 in breast cancer patients, we performed subgroup analysis between GATA3 and clinicopathological parameters, finding that overexpression of GATA3 is associated with positive ER (pooled RR = 3.155; 95% CI = 1.680–5.923; P = 0.000), positive PR (pooled RR = 3.949; 95% CI = 1.567–9.954; P = 0.004), lower nuclear grade (pooled RR = 0.435; 95% CI = 0.369–0.514; P = 0.000), and smaller tumor size (pooled RR = 0.816; 95% CI = 0.709–0.940; P = 0.005), which is consistent with several studies that have been published [25–27].